Keywords: novo, raises, diabetes, commitment, nordisk, increased, its
Novo Raises Diabetes Commitment
Article | 15 April 1996
- Novo Nordisk has increased its commitment to Anergen's IDDM-AnergiX drug for insulin-dependent diabetes, after encouraging data in preclinical tests.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
